Provided by Tiger Fintech (Singapore) Pte. Ltd.

NRX Pharmaceuticals Inc.

2.99
+0.01000.34%
Post-market: 2.990.00000.00%18:35 EDT
Volume:118.49K
Turnover:357.84K
Market Cap:58.32M
PE:-1.55
High:3.06
Open:2.98
Low:2.96
Close:2.98
Loading ...

NRX Pharmaceuticals Inc - Anticipates Priority Review Due to Ketamine Shortage

THOMSON REUTERS
·
05 Jun

NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Files Abbreviated New Drug Application (Anda) for Preservative-Free Iv Ketamine

THOMSON REUTERS
·
05 Jun

NRX Pharmaceuticals Inc - Nda Submission for NRX-100 in Suicidal Depression, Pdufa Expected Late 2025

THOMSON REUTERS
·
05 Jun

NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

TIPRANKS
·
28 May

NRX Pharmaceuticals Reports Reduced Net Loss of $5.5 Million in Q1 2025 Compared to $6.5 Million in Q1 2024

Reuters
·
22 May

NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21

TIPRANKS
·
22 May

NRX Pharmaceuticals Inc. to Present Company Update at Prestigious Wall Street Conference in Palm Beach

Reuters
·
21 May

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
17 May

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup

TIPRANKS
·
17 May

NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement

TIPRANKS
·
16 May

NRX Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

NRX Pharmaceuticals Q1 EPS $(0.34) Misses $(0.30) Estimate

Benzinga
·
16 May

BRIEF-NRX Pharmaceuticals Reports First Quarter 2025 Financial Results And Provides Corporate Update

Reuters
·
16 May

NRX Pharmaceuticals Gets $7.8 Million Debt Financing From Universal Capital

MT Newswires Live
·
15 May

Hope Therapeutics, Inc. a Subsidiary of NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel Hope Clinic Acquisitions

THOMSON REUTERS
·
15 May

Press Release: HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

Dow Jones
·
15 May

NRX Pharmaceuticals Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
14 May

NRX Pharmaceuticals to Acquire Kadima Neuropsychiatry Institute in California

MT Newswires Live
·
13 May

NRX Pharmaceuticals and HOPE Therapeutics Announce Agreement to Acquire Kadima Neuropsychiatry Institute to Expand Interventional Psychiatry Network

Reuters
·
13 May

Hope Therapeutics, Inc. and NRX Pharmaceuticals (Nasdaq:Nrxp) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the Hope Network of Interventional Psychiatry Clinics

THOMSON REUTERS
·
13 May